NEW YORK (360Dx) – Cancer detection firm Oncimmune today announced the first distribution deals for its autoantibody-based lung cancer test.

Under the terms of the deals, Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries. The agreements allow for the sale of the test as a central laboratory test while Oncimmune finishes the CE marking of a kit form of EarlyCDTLung.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.